[Present status in studying immunotherapy for acute leukemia and its perspective--Editorial]

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Immunotherapy is a key strategy for extending remission and eradicating minimal residual disease in acute leukemia.
• Current research explores four main immunotherapy types: monoclonal antibodies, adoptive cellular immunotherapy, cytokines/immune modulators, and leukemia vaccines.

Discussion:

• Monoclonal antibodies (Mabs) like Mylotarg, Campath-1H, and Rituximab have demonstrated efficacy in treating specific acute leukemia subtypes.
• Adoptive cellular immunotherapy utilizes various immune effector cells, while cytokines and immune modulators aim to enhance the immune response.
• Leukemia vaccines, particularly dendritic cell-based vaccines, are also under investigation for their therapeutic potential.

Key Insights:

• Monoclonal antibodies are currently the most effective immunotherapy for acute leukemia.
• Mylotarg (anti-CD33 Mab) shows good results in refractory/relapsed acute myeloid leukemia.
• Rituximab (anti-CD20 Mab) achieves high complete remission rates in B-cell prolymphocytic leukemia.

Outlook:

• Further clinical trials are necessary to validate the efficacy of adoptive cellular immunotherapy, cytokines, and leukemia vaccines.
• Ongoing research aims to optimize existing immunotherapies and develop novel approaches for acute leukemia treatment.
• The development of targeted immunotherapies holds significant promise for improving patient outcomes in acute leukemia.